bluebird bio reports new data from HGB-205 and HGB-206 studies of LentiGlobin at ASH

US biotech start-up bluebird bio (Nasdaq: BLUE) has presented new data from the ongoing HGB-205 and HGB-206 clinical studies evaluating its LentiGlobin BB305 product candidate in patients with beta-thalassemia major and severe sickle cell disease (SCD), at the 57th American Society of Hematology (ASH) Annual Meeting.

The data from the HGB-205 study were highlighted in an oral presentation by Marina Cavazzana, lead investigator of the HGB-205 study and professor of hematology at Paris Descartes University, head of the department of Biotherapy Hospital, the clinical research INSERM center of Biotherapy at Necker Enfants Malades, (Assistance Publique-Hôpitaux de Paris) and the Lymphohematopoiesis Laboratory, Institute of Genetic Diseases, Imagine, Paris, France. Data from the HGB-206 study were presented during a poster session by John Tisdale, senior investigator, molecular and clinical hematology branch at the National Institutes of Health.